Sabra Ebitda from 2010 to 2025

SBRA Stock  USD 17.61  0.17  0.96%   
Sabra Healthcare's EBITDA is increasing over the years with slightly volatile fluctuation. EBITDA is expected to dwindle to about 284 M. From 2010 to 2025 Sabra Healthcare EBITDA quarterly data regression line had arithmetic mean of  259,801,876 and r-squared of  0.46. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
101.7 M
Current Value
117.5 M
Quarterly Volatility
45.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sabra Healthcare financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sabra Healthcare's main balance sheet or income statement drivers, such as Depreciation And Amortization of 121.5 M, Interest Expense of 86.1 M or Selling General Administrative of 31.2 M, as well as many indicators such as Price To Sales Ratio of 9.78, Dividend Yield of 0.0646 or PTB Ratio of 1.53. Sabra financial statements analysis is a perfect complement when working with Sabra Healthcare Valuation or Volatility modules.
  
Check out the analysis of Sabra Healthcare Correlation against competitors.

Latest Sabra Healthcare's Ebitda Growth Pattern

Below is the plot of the Ebitda of Sabra Healthcare REIT over the last few years. It is Sabra Healthcare's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sabra Healthcare's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Sabra Ebitda Regression Statistics

Arithmetic Mean259,801,876
Geometric Mean181,054,866
Coefficient Of Variation59.89
Mean Deviation129,339,126
Median284,007,020
Standard Deviation155,599,719
Sample Variance24211.3T
Range513.6M
R-Value0.68
Mean Square Error13940T
R-Squared0.46
Significance0
Slope22,229,400
Total Sum of Squares363169.1T

Sabra Ebitda History

2025284 M
2024412.6 M
2023311.8 M
2022323.4 M
2021166.2 M
2020418 M
2019516.9 M

About Sabra Healthcare Financial Statements

Sabra Healthcare stakeholders use historical fundamental indicators, such as Sabra Healthcare's Ebitda, to determine how well the company is positioned to perform in the future. Although Sabra Healthcare investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sabra Healthcare's assets and liabilities are reflected in the revenues and expenses on Sabra Healthcare's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sabra Healthcare REIT. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA412.6 M284 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Sabra Healthcare REIT offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sabra Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sabra Healthcare Reit Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sabra Healthcare Reit Stock:
Check out the analysis of Sabra Healthcare Correlation against competitors.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Diversified REITs space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sabra Healthcare. If investors know Sabra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sabra Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.827
Dividend Share
1.2
Earnings Share
0.54
Revenue Per Share
3.009
Quarterly Revenue Growth
0.125
The market value of Sabra Healthcare REIT is measured differently than its book value, which is the value of Sabra that is recorded on the company's balance sheet. Investors also form their own opinion of Sabra Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Sabra Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sabra Healthcare's market value can be influenced by many factors that don't directly affect Sabra Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sabra Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sabra Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sabra Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.